Elsevier

Medical Hypotheses

Volume 48, Issue 4, April 1997, Pages 309-315
Medical Hypotheses

Urotherapy for patients with cancer

https://doi.org/10.1016/S0306-9877(97)90099-2Get rights and content

Abstract

Cancer cells release various antigens, some of which appear in the urine. Oral autourotherapy is suggested as a new treatment modality for cancer patients. It will provide the intestinal lymphatic system with the many tumor antigens against which antibodies may be produced. These antibodies may be pierced through the blood stream and attack the tumor and its cells.

References (96)

  • A. Miller et al.

    Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein

    J Neuroimmunol

    (1992)
  • H.B. Day

    Treatment of glomerulonephritis by antigen

    Lancet

    (1936)
  • E.M. Bricker

    Bladder substitution after pelvic evisceration

    Surg Clin N Am

    (1950)
  • D. Tapper et al.

    Lymphoid depletion in ileal loops: mechanism and clinical implications

    J Pediatr Surg

    (1976)
  • J.Y. Rivard et al.

    Colonic neoplasms following ureterosigmoidostomy

    J Urol

    (1975)
  • J.J. Carswell et al.

    Neoplasia at the site of ureterosigmoidostomy

    J Urol

    (1976)
  • A.J. Eraklis et al.

    Adenocarcinoma at the site of ureterosigmoidostomies for exstrophy of the bladder

    J Pediatr Surg

    (1978)
  • F. Burnet

    Immunological aspects of malignant disease

    Lancet

    (1967)
  • M. Droller

    Immunotherapy and genitourinary neoplasia

    Urol Clin N Am

    (1980)
  • R.S. Root-Benstein

    Causality, complementarity, evolution, and emergent properties

  • F.M. Burnet

    The concept of immunological surveillance

    Prog Exp Tumor Res

    (1970)
  • I. Hellstrom et al.

    Cell-mediated reactivity to antigens shared by Moloney virus induced lymphoma cells (LSTRA) and cells from certain 3-methylcholanthrene induced mouse sarcomas

    Int J Cancer

    (1979)
  • I. Hellstrom et al.

    Cell-mediated immunity against antigens common to tumor colonic carcinomas and fetal gut epithelium

    Int J Cancer

    (1970)
  • K.E. Hellstrom et al.

    Immunological approach to tumor therapy: monoclonal antibodies, tumor vaccines, and anti-idiotypes

  • P. Ehrlich
  • T. Watanabe et al.

    Human melanoma antigen AH is an autologous ganglioside related to GD2

    J Exp Med

    (1982)
  • R.K. Gupta et al.

    Prognostic significance of urinary antigen analysis by enzyme-linked immunosorbant assay in melanoma patients

    Diag Immunol

    (1983)
  • R.W. DeVere White et al.

    Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy

    J Urol

    (1992)
  • L. Lindholm et al.

    Monoclonal antibodies against gastro-interstinal tumor-associated antigens isolated as monosialogangliosides

    Int Arch Allergy Appl Immun

    (1983)
  • J. Holmgren et al.

    Detection by monoclonal antibody of carbohydrate antigen CA50 in serum of patients with carcinoma

    Br Med J

    (1984)
  • C. Dienst et al.

    CA 19-9, CA50 and CEA bei Pankreas and gastrointestinal Tumoren

    Medizin Klin

    (1987)
  • H.D. Bruhn et al.

    CA 50 im serum von Karzinom-Patienten

    Deutsch Med Wochenschr

    (1986)
  • F. Farinati et al.

    CA 50 determination in body fluids: can we screen patients at risk for gastric cancer?

    Int J Cancer

    (1991)
  • J.C. Hoffmann et al.

    A soluble form of the adhesion receptor CD58 (LFA-3) is present in human body fluids

    Eur J Immunol

    (1993)
  • M. Tobi et al.

    Urinary organ specific neoantigen. A potentially diagnostic test for colorectal cancer

    Dig Dis Sci

    (1995)
  • R.K. Boutwell

    Evidence that an elevated level of ornithine decerboxylase activity is an essential component of tumor promotion

    Adv Polyamine Res

    (1983)
  • A. Lipton et al.

    Urinary polyamine levels in patients with gastrointestinal malignancy

    Cancer

    (1975)
  • C. Loser et al.

    Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum and urine of 50 patients with colorectal cancer

    Cancer

    (1990)
  • Y. Matsumura et al.

    Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells

    Br Med J

    (1994)
  • Y. Matsumura et al.

    Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities

    J Pathol

    (1995)
  • B. Zbar et al.

    Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis

    Science

    (1971)
  • S.A. Rosenberg et al.

    Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

    N Engl J Med

    (1988)
  • I. Penn

    Tumors of the immunocompromised patient

    Annu Rev Med

    (1988)
  • F. Vanky et al.

    Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture — no correlation with the postsurgical clinical course

    Cancer Immunol Immunother

    (1987)
  • F. Vanky et al.

    Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes

    Int J Cancer

    (1982)
  • A. Knuth et al.

    Cytolytic T cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection

  • A.F. LoBuglio et al.

    A review of transfer factor immunotherapy in cancer

    Cancer

    (1974)
  • A.S. Levin et al.

    Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor

    J Clin Invest

    (1975)
  • View full text